Quick Answer
Krystal Biotech, Inc. reported R&D Expense of $58.05 million for fiscal year 2025.
Krystal Biotech, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $58.05M | +8.3% |
| 2024 | $53.58M | +15.4% |
| 2023 | $46.43M | +9.4% |
| 2022 | $42.46M | +52.3% |
| 2021 | $27.88M | +55.5% |
| 2020 | $17.94M | +14.9% |
| 2019 | $15.62M | +101.2% |
| 2018 | $7.76M | +141.9% |
| 2017 | $3.21M | +332.9% |
| 2016 | $741.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.59M | +7.9% | +1.2% |
| June 30, 2025 | $14.41M | -7.5% | +1.1% |
| March 31, 2025 | $14.26M | +30.1% | +5.5% |
| September 30, 2024 | $13.51M | +27.1% | -13.3% |
| June 30, 2024 | $15.58M | +28.3% | +42.2% |
| March 31, 2024 | $10.96M | -10.8% | +3.1% |
| September 30, 2023 | $10.63M | -7.7% | -12.5% |
| June 30, 2023 | $12.14M | +11.5% | -1.2% |
- Krystal Biotech, Inc. showed an increase of +8.3% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Krystal Biotech, Inc.’s r&d expense has grown by 7733.3% (from $741.0 thousand to $58.05 million).
- The most recent figure is from Krystal Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: